Late phase completed clinical trials investigating bromocriptine mesylate quick release as treatment of type 2 diabetes mellitus

Siamashvili, Maka

doi:10.1080/14656566.2020.1825683

Cited by 5 publications

(5 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hypoglycemia can cause dizziness, syncope, and even a sense of dying [ 13 ]. This negative emotional experience can lead patients to take “overcompensation behavior”, such as overly vigilant blood glucose monitoring, limiting physical activity, intentionally reducing the required drug dosage, or ingesting excessive carbohydrates to maintain blood glucose at a high level [ 14 , 15 ]. It has become a major obstacle to the control of blood sugar, which can lead to the occurrence or aggravation of complications in patients and have a negative impact on the management of diabetes [ 16 , 17 ].…”

Section: Introductionmentioning

confidence: 99%

The relationship between components of hypoglycemia worries and avoiding hypoglycemia behavior in type 2 diabetes mellitus with hypoglycemia: a network analysis

Wang

Cheng

et al. 2023

BMC Psychiatry

View full text Add to dashboard Cite

Background The fear of hypoglycemia in type 2 diabetes mellitus (T2DM) patients with hypoglycemia has seriously affected their quality of life. They are always afraid of hypoglycemia and often take excessive action to avoid it. Yet, researchers have investigated the relationship between hypoglycemia worries and excessive avoiding hypoglycemia behavior using total scores on self-report measures. However, network analysis studies of hypoglycemia worries and excessive avoiding hypoglycemia behavior in T2DM patients with hypoglycemia are lacking. Purpose The present study investigated the network structure of hypoglycemia worries and avoiding hypoglycemia behavior in T2DM patients with hypoglycemia and aimed to identify bridge items to help them correctly treat hypoglycemia and properly deal with hypoglycemia fear. Methods A total of 283 T2DM patients with hypoglycemia were enrolled in our study. Hypoglycemia worries and avoiding hypoglycemia behavior were evaluated with the Hypoglycemia Fear Scale. Network analyses were used for the statistical analysis. Results B9 “Had to stay at home for fear of hypoglycemia” and W12 “I am worried that hypoglycemia will affect my judgment” have the highest expected influences in the present network. In the community of hypoglycemia worries, W17 “I worry about hypoglycemia during sleep” has the highest bridge expected influence. And in the community of avoiding hypoglycemia behavior, B9 “Had to stay at home for fear of hypoglycemia” has the highest bridge expected influence. Conclusion Complex patterns of associations existed in the relationship between hypoglycemia worries and avoiding hypoglycemia behavior in T2DM patients with hypoglycemia. From the perspective of network analysis, B9 “Had to stay at home for fear of hypoglycemia” and W12 “I am worried that hypoglycemia will affect my judgment” have the highest expected influence, indicating their highest importance in the network. W17 “I worry about hypoglycemia during sleep” aspect of hypoglycemia worries and B9 “Had to stay at home for fear of hypoglycemia” aspect of avoiding hypoglycemia behavior have the highest bridge expected influence, indicating they have the strongest connections with each community. These results have important implications for clinical practice, which provided potential targets for interventions to reduce hypoglycemia fear and improve the quality of life in T2DM patients with hypoglycemia.

show abstract

Section: Introductionmentioning

confidence: 99%

The relationship between components of hypoglycemia worries and avoiding hypoglycemia behavior in type 2 diabetes mellitus with hypoglycemia: a network analysis

Wang

Cheng

et al. 2023

BMC Psychiatry

View full text Add to dashboard Cite

show abstract

“…15 Moreover, a newly developed rapidrelease formulation of bromocriptine mesylate has been approved by FDA for the management of T2DM. 24,260 Improvements of extrapyramidal symptoms in hepatic encephalopathy have been reported by some researchers after adding bromocriptine therapy as third line agent to the conventional therapy. 201 Similarly, several case reports has been filed by researchers against the successful use of bromocriptine therapy as an adjunct therapy to the primary treatment in NMS, 178,180,184 alcohol withdrawal syndrome, 18,192 HC 211 and in various neurological disorders, 216 whereas to check its effectiveness in cognitive control and working memory as well as in endometriosis, etc, various animal and human studies have also been conducted.…”

Section: Current Clinical Status Of Bromocriptinementioning

confidence: 97%

“…Previously, it was broadly marketed for lactation suppression, but because of the incidence of seizures, stroke and myocardial infarction, it is no longer being used for this problem 15 . Moreover, a newly developed rapid‐release formulation of bromocriptine mesylate has been approved by FDA for the management of T2DM 24,260 …”

Section: Current Clinical Status Of Bromocriptinementioning

confidence: 99%

See 1 more Smart Citation

Bromocriptine therapy: Review of mechanism of action, safety and tolerability

Naz

Malik

Riaz

et al. 2022

Clin Exp Pharma Physio

View full text Add to dashboard Cite

Bromocriptine is a sympatholytic dopamine D2 receptor agonist with remarkable bioactivities. It has been used clinically as a prescription drug for more than 30 years to treat hyperprolactinemia associated conditions, Parkinson's disease, acromegaly, prolactinomas and other pituitary hormone dependent adenomas and recently, diabetes mellitus as well as various other disorders. Long‐term treatment with bromocriptine has minimal or no harmful effects on renal, hepatic, cardiac or hematologic functions. This review article was planned to study the hypothetical and proposed mechanism of action as well as provide a brief discussion about its safety issues and tolerability. Bromocriptine represents an attractive option with high efficacy and safety profile for hyperprolactinemia‐associated conditions, acromegaly, parkinsonism, type 2 diabetes mellitus and various other diseases in a variety of dosage forms for best possible beneficial effects. It appeared to be an effective and safe addition to the pharmacopoeia of drugs for the treatment of a vast variety of diseases as monotherapy or in combination with other drugs.

show abstract

“…Plasma levels of the pro-inflammatory cytokines such as IL-1B and IL-18, chemokine CCL2/ MCP-1/, and the pro-inflammatory hormone prolactin, all of which are elevated and linked to accelerated cardiometabolic illness, were decreased as a result of bromocriptine therapy 7 , 22 , 23 . The key risk factors for CVD including the inflammation, sympathetic tone, endothelial nitric oxide synthase uncoupling, and increased postprandial lipids are decreased by circadian-timed bromocriptine medication 24 . A study by Fouad et al showed that BROMOCRIPTINE have played a significant role in reducing the levels of cardiac markers like Troponin I, TNF alpha and LDH-1 25 .…”

Section: Introductionmentioning

confidence: 99%

Bromocriptine: does this drug of Parkinson’s disease have a role in managing cardiovascular diseases?

Kutikuppala,

Sharma,

Chavan

et al. 2023

Annals of Medicine &Amp; Surgery

View full text Add to dashboard Cite

Cardiovascular disease (CVD) is the most common cause of morbidity and mortality worldwide. Bromocriptine is a partial antagonist for D1 dopamine receptors while also serving as a selective agonist on D2 dopamine receptors as a dopamine receptor agonist. Apart from prolactin inhibiting action, bromocriptine has some beneficial effects on the blood pressure, plasma norepinephrine levels and vascular resistance. Dopamine D2 receptor activation of bromocriptine is associated with the antihypertensive effect, which lowers blood pressure via inhibiting sympathetic nerve activity and Na/K ATPase activity. Plasma levels of the pro-inflammatory cytokines such as IL-1B and IL-18, chemokine CCL2/ MCP-1/, and the pro-inflammatory hormone prolactin, all of which are elevated and linked to accelerated cardiometabolic illness, were decreased because of bromocriptine therapy. The most common side effects of Bromocriptine use are dizziness, nausea, headache, vomiting and hypotension. Bromocriptine is mainly contraindicated in patients with syncope with hypotension, psychosis, and type I diabetes mellitus. We suggest that developing therapies directed to increase D2 receptor expression and function by drugs like Bromocriptine can provide practical and novelistic approaches to prevent and manage myocardial and renal injury in the cardiovascular disease patients.

show abstract

Late phase completed clinical trials investigating bromocriptine mesylate quick release as treatment of type 2 diabetes mellitus

Cited by 5 publications

References 22 publications

The relationship between components of hypoglycemia worries and avoiding hypoglycemia behavior in type 2 diabetes mellitus with hypoglycemia: a network analysis

The relationship between components of hypoglycemia worries and avoiding hypoglycemia behavior in type 2 diabetes mellitus with hypoglycemia: a network analysis

Bromocriptine therapy: Review of mechanism of action, safety and tolerability

Bromocriptine: does this drug of Parkinson’s disease have a role in managing cardiovascular diseases?

Contact Info

Product

Resources

About